Literature DB >> 3117548

Construction of a model for the aggregation and cross-linking region (7S domain) of type IV collagen based upon an evaluation of the primary structure of the alpha 1 and alpha 2 chains in this region.

B Siebold1, R A Qian, R W Glanville, H Hofmann, R Deutzmann, K Kühn.   

Abstract

The amino acid sequence of the 212-residues-long N-terminal aggregation and cross-linking region of the alpha 2(IV) chain of human basement membrane collagen is presented. Comparing this with the primary structure of alpha 1(IV)7S [Glanville et al. (1985) Eur. J. Biochem. 152, 213-219] revealed a high degree of similar subdivisions in three functional regions. These are the 21-residue-long N-terminal non-triple-helical regions (NH1) containing cysteine and lysine residues which are putative cross-linking sites, a 117-residue-long triple-helical region (TH1) responsible for the aggregation of four molecules to form the 7S domain and which also possess cross-linking sites, and finally a 10-residue-long non-triple-helical region (NH2) which introduces the first of many flexible areas into the triple helical body of the molecule [Hofmann et al. (1984) J. Mol. Biol. 172, 325-343]. Computer calculations of interaction scores between parallel and antiparallelly aligned triple-helical regions (TH1) of the 7S domain allowed the prediction of a detailed model for the structure of the 7S complex which agreed well with models based primarily on electron micrographs of rotary shadowed type IV collagen tetramers. The results indicated that the assembly of the 7S domain is directed by hydrophobic interactions and is self-limiting to a tetramer. The most favourable chain configuration is alpha 2-alpha 1-alpha 1.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117548     DOI: 10.1111/j.1432-1033.1987.tb13455.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  A novel chain of basement membrane-associated collagen as revealed by biochemical and immunohistochemical characterizations of the epitope recognized by a monoclonal antibody against human placenta basement membrane collagen.

Authors:  J Kino; E Adachi; T Yoshida; C Asamatsu; K Nakajima; K Yamamoto; T Hayashi
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 2.  Basement membranes: cell scaffoldings and signaling platforms.

Authors:  Peter D Yurchenco
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

3.  Type IV collagen lateral associations in the EHS tumor matrix. Comparison with amniotic and in vitro networks.

Authors:  P D Yurchenco; G C Ruben
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

4.  Alpha 1(IV) and alpha 2(IV) collagen genes are regulated by a bidirectional promoter and a shared enhancer.

Authors:  P D Burbelo; G R Martin; Y Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Lysyl Oxidase-like-2 Cross-links Collagen IV of Glomerular Basement Membrane.

Authors:  Carolina Añazco; Alberto J López-Jiménez; Mohamed Rafi; Lorenzo Vega-Montoto; Ming-Zhi Zhang; Billy G Hudson; Roberto M Vanacore
Journal:  J Biol Chem       Date:  2016-10-21       Impact factor: 5.157

Review 6.  Developmental and pathogenic mechanisms of basement membrane assembly.

Authors:  Peter D Yurchenco; Bruce L Patton
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Chemistry of collagen cross-links: glucose-mediated covalent cross-linking of type-IV collagen in lens capsules.

Authors:  A J Bailey; T J Sims; N C Avery; C A Miles
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

8.  Chimeric protein identification of dystrophic, Pierson and other laminin polymerization residues.

Authors:  Karen K McKee; Maya Aleksandrova; Peter D Yurchenco
Journal:  Matrix Biol       Date:  2018-03-03       Impact factor: 11.583

Review 9.  Beyond proteases: Basement membrane mechanics and cancer invasion.

Authors:  Julie Chang; Ovijit Chaudhuri
Journal:  J Cell Biol       Date:  2019-07-17       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.